Log in

NASDAQ:TCRR - Tcr2 Therapeutics Stock Price, Forecast & News

$6.58
-0.16 (-2.37 %)
(As of 03/31/2020 06:00 AM ET)
Today's Range
$6.04
Now: $6.58
$7.22
50-Day Range
$6.01
MA: $10.62
$15.19
52-Week Range
$5.84
Now: $6.58
$21.45
Volume88,691 shs
Average Volume83,569 shs
Market Capitalization$158.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCRR
CUSIPN/A
CIKN/A
Phone617-949-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-24,250,000.00

Miscellaneous

Employees47
Market Cap$158.42 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.


Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has Tcr2 Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR stock has decreased by 23.3% and is now trading at $6.58. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tcr2 Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tcr2 Therapeutics.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 6th 2020. View our earnings forecast for Tcr2 Therapeutics.

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) announced its quarterly earnings data on Monday, March, 30th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.10. View Tcr2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

2 brokerages have issued 1 year target prices for Tcr2 Therapeutics' stock. Their forecasts range from $16.00 to $19.00. On average, they expect Tcr2 Therapeutics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price. View analysts' price targets for Tcr2 Therapeutics.

Has Tcr2 Therapeutics been receiving favorable news coverage?

Media headlines about TCRR stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tcr2 Therapeutics earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutTcr2 Therapeutics.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 801,100 shares, a drop of 8.4% from the February 27th total of 875,000 shares. Based on an average daily trading volume, of 77,700 shares, the days-to-cover ratio is presently 10.3 days. Currently, 6.8% of the shares of the stock are short sold. View Tcr2 Therapeutics' Current Options Chain.

Who are some of Tcr2 Therapeutics' key competitors?

What other stocks do shareholders of Tcr2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Exxon Mobil (XOM), Harpoon Therapeutics (HARP), II-VI (IIVI) and Novavax (NVAX).

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
  • Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $6.58.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $158.42 million. The company earns $-24,250,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe. View additional information about Tcr2 Therapeutics.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is http://www.tcr2.com/.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]


MarketBeat Community Rating for Tcr2 Therapeutics (NASDAQ TCRR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote "Outperform" if you believe TCRR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel